Highest development stage: Approved by US FDA in 1998

Development status: Approved, off-patent, discontinued in most countries

Gram-positive activity

Mechanism of Action/Target pathogen: Binds to the bacterial 50S ribosomal subunit and inhibits the elongation process of protein synthesis; against M. pneumoniae, activity was similar to erythromycin, roxithromycin and clarithromycin

Additional information: Pristinamycin-derivative. Intravenous application. Mixture of 30% quinupristin (derived from pristinamycin IA) to 70% dalfopristin (derived from pristinamycin IIA);Georgopoulos A, Breyer S, Feistauer S, et al. Bactericidal effect of RP 59500 against staphylococci wth different pheotypes in a diffusion chamber model in rabbits. 32nd-Intersci-Conf-Antimicrobial-Agents-Chemother 1992; 329.